https://ir.hyperiondefi.com/ https://ir.hyperiondefi.com/news-events/press-releases https://ir.hyperiondefi.com/news-events/ir-calendar https://ir.hyperiondefi.com/news-events/presentations https://ir.hyperiondefi.com/news-events/annual-shareholder-meeting https://ir.hyperiondefi.com/news-events/email-alerts https://ir.hyperiondefi.com/company-information https://ir.hyperiondefi.com/company-information/executive-team https://ir.hyperiondefi.com/company-information/contacts https://ir.hyperiondefi.com/company-information/information-request https://ir.hyperiondefi.com/company-information/faq https://ir.hyperiondefi.com/financial-information/financial-results https://ir.hyperiondefi.com/financial-information/income-statement https://ir.hyperiondefi.com/financial-information/balance-sheet https://ir.hyperiondefi.com/financial-information/cash-flow https://ir.hyperiondefi.com/stock-data/quote-chart https://ir.hyperiondefi.com/stock-data/historical-data https://ir.hyperiondefi.com/stock-data/analyst-coverage https://ir.hyperiondefi.com/sec-filings/all-sec-filings https://ir.hyperiondefi.com/sec-filings/annual-reports https://ir.hyperiondefi.com/sec-filings/quarterly-reports https://ir.hyperiondefi.com/sec-filings/section-16-filings https://ir.hyperiondefi.com/governance https://ir.hyperiondefi.com/governance/board-of-directors https://ir.hyperiondefi.com/governance/board-committees https://ir.hyperiondefi.com/governance/governance-documents https://ir.hyperiondefi.com/news-events/press-releases/detail/307/hyperion-defi-reports-4q-and-fy-2025-financial-results-with-quarter-over-quarter-growth-of-64-revenue-and-87-adjusted-gross-profit 2026-03-26T07:00:07-04:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/306/hyperion-defi-enters-haus-agreement-with-silhouette 2026-03-24T08:00:17-04:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/305/hyperion-defi-schedules-fourth-quarter-and-full-year-2025-earnings-call-for-thursday-march-26-at-8-00-a-m-et 2026-03-17T09:00:12-04:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/304/hyperion-defi-announces-private-lending-pool-built-by-hyperlend 2026-03-09T08:00:05-04:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/303/hyperion-defi-announces-institutional-volatility-income-vault-built-on-rysk-protocol 2026-02-04T08:00:11-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/302/hyperion-defi-issues-letter-to-shareholders 2026-01-12T08:00:15-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/301/hyperion-defi-appoints-hyunsu-jung-as-chief-executive-officer 2026-01-05T08:00:09-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/300/hyperion-defi-announces-receipt-of-kinetiq-airdrop-partnership-with-native-markets-and-purchase-of-150000-additional-hype 2025-12-04T08:00:04-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/288/hyperion-defi-reports-third-quarter-2025-financial-results-with-record-net-income-of-6-6-million 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/289/hyperion-defi-schedules-third-quarter-2025-earnings-call-for-november-13-2025 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/290/hyperion-defi-announces-strategic-partnership-with-felix-to-launch-hip-3-powered-perpetual-futures-market 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/291/hyperion-defi-announces-appointment-of-david-knox-as-chief-financial-officer 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/292/hyperion-defi-adds-10m-in-hype-to-its-treasury-holdings 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/293/hyperion-defi-enters-into-first-haus-agreement-with-proprietary-trading-firm-credo 2025-11-25T10:41:52-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/294/hyperion-defi-strengthens-leadership-team-with-key-appointments-to-accelerate-defi-strategy 2025-11-25T10:41:53-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/295/hyperion-defi-provides-corporate-update-and-reports-second-quarter-2025-financial-results 2025-11-25T10:41:53-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/296/hyperion-defi-to-report-second-quarter-2025-results-on-wednesday-august-13-2025 2025-11-25T10:41:53-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/297/hyperion-defi-purchases-additional-5-million-in-hype-for-kinetiq-ihype-strategy 2025-11-25T10:41:54-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/298/hyperion-defi-to-host-corporate-update-event-to-discuss-strategic-evolution-from-eyenovia-and-the-future-of-on-chain-finance-on-july-29-2025 2025-11-25T10:41:54-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/299/hyperion-defi-adds-5-million-in-hype-to-its-treasury-holdings 2025-11-25T10:41:54-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/85/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc 2025-11-25T10:41:29-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/86/eyenovia-adds-10-million-in-hype-to-its-treasury-holdings-in-preparation-for-strategic-onchain-engagement 2025-11-25T10:41:29-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/87/eyenovia-announces-co-branded-validator-with-kinetiq 2025-11-25T10:41:29-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/88/eyenovia-announces-closing-of-50-million-private-placement-successful-accumulation-of-more-than-one-million-hype-tokens-and-update-on-its-optejet-development-program 2025-11-25T10:41:29-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/89/eyenovia-announces-appointment-of-a-strategic-advisor-for-digital-asset-treasury-strategy-and-amendment-of-debt-agreement-with-avenue-capital-group 2025-11-25T10:41:29-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/90/eyenovia-announces-50-million-investment-to-launch-a-hyperliquid-hype-token-cryptocurrency-treasury-reserve-strategy 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/91/eyenovia-provides-updates-on-potential-merger-with-betaliq-and-development-of-the-optejet-user-filled-device-ufd-and-reports-first-quarter-2025-financial-results 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/92/eyenovia-provides-development-update-on-optejet-user-filled-device-ufd 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/93/eyenovia-enters-into-non-binding-letter-of-intent-to-effect-reverse-merger-with-betaliq 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/94/eyenovia-regains-compliance-with-all-nasdaq-continued-listing-requirements 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/95/eyenovia-inc-announces-debt-restructuring-including-amendment-to-senior-secured-debt-improving-cash-runway-to-allow-for-the-evaluation-of-strategic-alternatives 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/96/eyenovia-announces-progress-on-next-generation-user-filled-optejet-dispensing-device 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/97/eyenovia-announces-1-for-80-reverse-stock-split 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/98/eyenovia-announces-leading-proxy-advisory-firms-iss-and-glass-lewis-recommend-eyenovia-stockholders-vote-for-proposed-reverse-stock-split-at-upcoming-special-meeting-of-stockholders 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/99/eyenovia-engages-chardan-as-advisor-for-review-of-strategic-alternatives 2025-11-25T10:41:30-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/100/eyenovia-inc-announces-pricing-of-1-9-million-registered-direct-offering 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/101/eyenovia-inc-announces-pricing-of-1-3-million-registered-direct-offering 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/102/eyenovia-provides-update-on-restructuring-efforts 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/103/eyenovia-provides-update-on-phase-3-chaperone-study 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/104/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/105/eyenovia-to-report-third-quarter-2024-results-on-tuesday-november-12th 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/106/eyenovia-announces-publication-of-study-demonstrating-favorable-impact-on-the-ocular-surface-of-medication-delivered-with-the-optejet 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/107/eyenovia-announces-presentation-of-phase-3-clobetasol-study-results-at-theamerican-academy-of-ophthalmology-aao-2024-expo 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/108/eyenovia-announces-commencement-of-manufacturing-of-itsadvanced-second-generation-optejet-device 2025-11-25T10:41:31-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/109/eyenovia-inc-announces-pricing-of-4-million-registered-direct-offering 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/110/eyenovia-announces-launch-and-commercial-availability-of-clobetasol-propionate-ophthalmic-suspension-0-05-for-post-operative-inflammation-and-pain-following-ocular-surgery 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/111/eyenovia-announces-taiwan-export-license-approval-to-commence-shipment-of-clobetasol-propionate-ophthalmic-suspension-0-05-to-the-u-s 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/112/eyenovia-announces-appointment-of-experienced-finance-and-accounting-executive-andrew-jones-as-chief-financial-officer 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/113/eyenovia-announces-closing-of-public-offering 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/114/eyenovia-announces-pricing-of-5-14-million-public-offering 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/115/eyenovia-inc-announces-proposed-public-offering 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/116/eyenovia-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/117/eyenovia-reports-second-quarter-2024-financial-results-and-provides-corporate-update 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/118/eyenovia-to-report-second-quarter-2024-results-on-monday-august-12th 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/119/eyenovia-and-formosa-pharmaceuticals-initiate-co-development-of-clobetasol-propionate-ophthalmic-suspension-0-05-for-the-treatment-of-acute-dry-eye-disease-in-the-u-s 2025-11-25T10:41:32-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/120/eyenovia-sgn-nanopharma-announce-collaboration-agreement-to-develop-novel-treatment-for-chronic-dry-eye-disease 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/121/eyenovia-and-senju-pharmaceutical-co-ltd-sign-collaboration-agreement-for-potential-new-treatment-for-chronic-dry-eye-disease 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/122/eyenovia-announces-pricing-of-5m-registered-direct-offering 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/123/eyenovia-reports-first-quarter-2024-financial-results-and-provides-updates-on-its-myopia-phase-iii-program-and-its-two-fda-approved-commercial-products-mydcombi-and-clobetasol 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/124/eyenovia-to-report-first-quarter-2024-results-on-wednesday-may-15th 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/125/eyenovia-provides-clinical-and-scientific-update-on-fda-approved-products-mydcombi-and-clobetasol-propionate-ophthalmic-suspension 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/126/eyenovia-announces-updated-strategy-and-corporate-priorities-to-focus-on-shareholder-value-generation-and-immediate-commercial-opportunities 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/127/eyenovia-to-feature-its-suite-of-commercial-products-and-the-optejet-dispenser-at-upcoming-national-eyecare-meetings 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/128/eyenovia-reports-fourth-quarter-and-full-year-2023-financial-results-andprovides-business-update 2025-11-25T10:41:33-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/129/novabay-pharmaceuticals-and-eyenovia-to-co-promoteprescription-ophthalmic-products-to-u-s-eyecare-professionals 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/130/eyenovia-to-report-fourth-quarter-2023-results-and-provide-business-update-onmonday-march-18th 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/131/eyenovia-congratulates-formosa-pharmaceuticals-on-fda-approval-ofclobetasol-propionate-ophthalmic-suspension-0-05for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/132/eyenovia-announces-fda-approval-of-redwood-city-as-commercial-manufacturing-facility 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/133/eyenovia-re-acquires-development-and-commercialization-rights-to-micropine-in-the-u-s-and-canada 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/134/eyenovia-reports-third-quarter-2023-financial-results-and-provides-business-update 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/135/eyenovia-to-report-third-quarter-2023-results-on-monday-november-13 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/136/eyenovia-announces-fda-approval-of-coastline-international-as-contract-manufacturer-to-initiate-mydcombi-commercial-production 2025-11-25T10:41:34-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/137/eyenovia-to-sponsor-course-on-drug-delivery-innovation-at-ijcahpos-51st-annual-continuing-education-ace-program 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/138/eyenovia-to-present-data-on-preservative-free-microbial-integrity-of-the-optejet 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/139/eyenovia-to-participate-in-panel-discussion-at-cantor-global-healthcare-conference 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/140/eyenovia-to-present-at-upcoming-h-c-wainwright-25th-annual-global-investment-conference 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/141/eyenovia-announces-12-million-registered-direct-offering 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/142/eyenovia-acquires-u-s-commercial-rights-to-app13007-clobetasol-propionate-ophthalmic-nanosuspension-0-05-from-formosa-pharmaceuticals 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/143/eyenovia-reports-second-quarter-2023-financial-results-and-provides-business-update 2025-11-25T10:41:35-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/144/eyenovia-to-present-at-upcoming-h-c-wainwright-3rd-annual-ophthalmology-virtual-conference 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/145/eyenovia-to-report-second-quarter-2023-results-on-thursday-august-10 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/146/eyenovia-announces-first-commercial-sale-of-mydcombi 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/147/eyenovia-announces-addition-to-russell-2000-and-russell-3000-indexes 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/148/eyenovia-expands-its-us-manufacturing-capabilities 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/149/eyenovia-announces-presentation-at-the-octane-ophthalmology-tech-forum-2023 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/150/eyenovia-reports-first-quarter-2023-financial-results-and-provides-business-update 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/151/eyenovia-announces-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis-which-also-leverages-the-companys-proprietary-optejet-device-platform 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/152/eyenovia-to-report-first-quarter-2023-results-on-thursday-may-11 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/153/eyenovia-announces-poster-presentation-at-arvo-2023 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/154/eyenovia-reports-fourth-quarter-2022-financial-results-and-provides-business-update 2025-11-25T10:41:36-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/155/eyenovia-to-report-fourth-quarter-and-full-year-2022-results-on-thursday-march-30 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/156/eyenovia-announces-independent-director-stephen-benjamin-to-step-down-to-assume-role-ofhead-of-white-houses-office-of-public-engagement 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/157/eyenovia-announces-development-collaboration-agreement-with-formosa-pharmaceuticals 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/158/eyenovia-reveals-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/159/eyenovia-announces-participation-at-the-2023-international-consumer-electronics-show 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/160/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-forin-office-pupil-dilation 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/161/eyenovia-announces-promotion-of-bren-kern-to-chief-operating-officer-and-corporate-vice-president 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/162/eyenovia-announces-15-million-credit-facility-with-avenue-venture-debt-fund 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/163/eyenovia-to-present-at-upcoming-btig-ophthalmology-day 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/164/eyenovia-reports-third-quarter-2022-financial-results-and-provides-business-update 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/165/eyenovia-to-report-third-quarter-2022-results-on-thursday-november-10 2025-11-25T10:41:37-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/166/eyenovia-to-present-at-the-american-academy-of-optometrys-annual-meeting 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/167/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/168/eyenovia-announces-planned-retirement-of-lead-independent-director-ken-lee-jr 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/169/eyenovia-to-present-at-upcoming-healthcare-conferences 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/170/eyenovia-to-participate-in-multiple-medical-meetings-in-september 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/171/eyenovia-reports-second-quarter-2022-financial-results 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/172/eyenovia-to-report-second-quarter-2022-results-on-wednesday-august-10 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/173/eyenovia-announces-appointment-of-ophthalmic-industry-veteran-michael-rowe-as-chief-executive-officer-and-board-member 2025-11-25T10:41:38-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/174/eyenovia-provides-manufacturing-update-and-announces-appointment-of-bren-kern-as-svp-of-manufacturing-and-operations 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/175/eyenovia-announces-appointments-of-dr-ellen-strahlman-and-dr-ram-palanki-as-new-and-independent-members-of-its-board-of-directors 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/176/eyenovia-strategic-partner-arctic-vision-enrolls-first-patient-in-phase-iii-clinical-trial-of-arvn003-microline-for-presbyopia-in-china 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/177/update-eyenovia-announces-virtual-2022-annual-meeting-of-stockholders 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/178/eyenovia-announces-virtual-2022-annual-meeting-of-stockholders 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/179/eyenovia-announces-planned-chief-executive-officer-transition 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/180/eyenovia-reports-first-quarter-2022-financial-results 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/181/eyenovia-to-report-first-quarter-2022-results-on-thursday-may-12 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/182/eyenovia-ceo-cmo-and-chairman-dr-sean-ianchulev-to-present-at-eyecelerator-american-society-of-cataract-and-refractive-surgery-ascrs-2022 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/183/eyenovia-reports-fourth-quarter-and-full-year-2021-financial-results 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/184/eyenovia-to-report-fourth-quarter-and-full-year-2021-results-on-monday-march-28 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/185/eyenovia-announces-positive-study-results-demonstrating-that-its-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions-to-a-level-comparable-with-non-preserved-solutions 2025-11-25T10:41:39-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/186/eyenovia-strengthens-balance-sheet-with-a-15-million-institutional-capital-investment-from-armistice-capital-master-fund-ltd 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/187/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/188/eyenovia-announces-changes-to-board-of-directors 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/189/eyenovia-reports-third-quarter-2021-financial-results 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/190/eyenovia-to-participate-in-myopia-panel-discussion-at-the-eyeceleratoraao-2021-meeting 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/191/correcting-and-replacing-eyenovia-to-report-third-quarter-2021-results-on-wednesday-november-10 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/192/eyenovia-to-report-third-quarter-2021-results-on-thursday-november-11 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/193/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/194/eyenovia-announces-reclassification-of-mydcombitm-as-drug-device-combination-product-by-fda 2025-11-25T10:41:40-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/195/eyenovia-reports-second-quarter-2021-financial-results 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/196/eyenovia-to-report-second-quarter-2021-results-on-wednesday-august-11 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/197/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/198/eyenovia-to-participate-in-two-upcoming-investor-conferences 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/199/eyenovia-highlights-recent-progress-in-three-phase-3-programs-nda-review-progress-and-licensing-agreements-totaling-up-to-100-million-in-potential-pre-commercial-revenue 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/200/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/201/eyenovia-reports-first-quarter-2021-financial-results 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/202/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/203/eyenovia-to-report-first-quarter-2021-results-on-wednesday-may-12 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/204/eyenovia-announces-appointment-of-renowned-ophthalmologist-and-scientific-leader-dr-julia-haller-to-its-board-of-directors 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/205/eyenovia-reports-fourth-quarter-and-full-year-2020-financial-results 2025-11-25T10:41:41-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/206/eyenovia-and-eversana-announce-partnership-to-support-the-potential-launch-and-commercialization-of-mydcombi-for-mydriasis 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/207/eyenovia-to-report-fourth-quarter-and-full-year-2020-results-on-thursday-march-25 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/208/eyenovia-announces-publication-of-mist-pivotal-studies-demonstrating-the-efficacy-and-safety-of-its-map-fixed-combination-tropicamide-phenylephrine-product-for-mydriasis 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/209/eyenovia-to-participate-in-the-33rd-annual-roth-conference 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/210/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/211/eyenovia-to-host-key-opinion-leader-webinar-on-presbyopia 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/212/eyenovia-to-present-at-the-ophthalmology-innovation-summit-ois-presbyopia-innovation-showcase 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/213/eyenovia-to-participate-in-presbyopia-panel-discussion-at-the-lifesci-partners-10th-annual-corporate-access-event 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/214/eyenovia-submits-new-drug-application-to-fda-for-pharmacologic-mydriasis-with-mydcombi-targeting-80-million-patient-encounters-in-the-u-s-annually 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/215/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/216/eyenovia-announces-fda-acceptance-of-ind-for-microline-for-presbyopia-clearing-path-to-initiate-phase-3-vision-trial-by-year-end 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/217/eyenovia-reports-third-quarter-2020-financial-results 2025-11-25T10:41:42-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/218/eyenovia-to-report-third-quarter-2020-results-on-tuesday-november-10 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/219/eyenovia-to-host-investor-call-to-discuss-recent-licensing-agreements-resulting-in-total-potentiallicense-payments-and-development-cost-reimbursement-and-savings-of-approximately-100-million 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/220/eyenovia-to-present-clinical-study-updates-at-the-american-academy-of-optometry-annual-meeting 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/221/eyenovia-to-present-at-the-22nd-annual-h-c-wainwright-global-investment-conference 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/222/eyenovia-inc-announces-underwriters-full-exercise-of-over-allotment-option-in-public-offering 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/223/eyenovia-inc-announces-closing-of-offering-of-common-stock 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/224/eyenovia-inc-prices-public-offering-of-common-stock 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/225/eyenovia-inc-announces-proposed-public-offering-of-common-stock 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/226/eyenovia-reports-second-quarter-2020-financial-results 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/227/eyenovia-and-arctic-vision-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-micropine-and-microline-in-greater-china-and-south-korea 2025-11-25T10:41:43-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/228/eyenovia-announces-conference-call-and-webcast-for-second-quarter-2020-financial-results 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/229/eyenovia-resumes-recruitment-of-phase-iii-chaperone-study-for-progressive-myopia 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/230/eyenovia-inc-announces-adjournment-of-2020-annual-meeting-of-stockholders-to-june-30-2020-and-change-to-a-virtual-meeting-format 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/231/eyenovia-announces-intention-to-adjourn-2020-annual-meeting-of-stockholders-to-june-30-2020-and-change-to-a-virtual-meeting-format 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/232/eyenovia-reports-first-quarter-2020-financial-results 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/233/eyenovia-announces-conference-call-and-webcast-for-first-quarter-2020-financial-results 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/234/eyenovia-reports-fourth-quarter-and-full-year-2019-financial-results 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/235/eyenovia-inc-announces-closing-of-approximately-6-0-million-private-placement 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/236/eyenovia-inc-announces-approximately-6-0-million-private-placement 2025-11-25T10:41:44-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/237/eyenovia-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2019-financial-results 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/238/eyenovia-to-participate-in-two-upcoming-investor-conferences 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/239/eyenovia-expands-scientific-advisory-board-with-two-experts-in-optometry 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/240/eyenovia-reports-third-quarter-2019-financial-results 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/241/eyenovia-announces-conference-call-and-webcast-for-third-quarter-2019-financial-results 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/242/eyenovia-advances-microline-for-the-treatment-of-presbyopia-towards-phase-iii-development-and-reprioritizes-late-stage-ophthalmology-pipeline 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/243/eyenovia-to-participate-in-multiple-upcoming-medical-meetings 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/244/eyenovia-to-present-at-two-upcoming-investor-conferences 2025-11-25T10:41:45-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/245/eyenovia-reports-second-quarter-2019-financial-results 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/246/eyenovia-announces-conference-call-and-webcast-for-second-quarter-2019-financial-results 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/247/eyenovia-inc-announces-underwriters-full-exercise-of-over-allotment-option-in-public-offering 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/248/eyenovia-inc-announces-closing-of-public-offering 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/249/eyenovia-inc-prices-public-offering-of-common-stock 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/250/eyenovia-inc-announces-proposed-public-offering-of-common-stock 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/251/eyenovia-enrolls-first-patient-in-phase-iii-chaperone-study-for-progressive-myopia 2025-11-25T10:41:46-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/252/eyenovia-reports-first-quarter-2019-financial-results 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/253/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs-asoa-annual-meeting 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/254/eyenovia-announces-conference-call-and-webcast-for-first-quarter-2019-financial-results 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/255/eyenovia-reports-fourth-quarter-and-full-year-2018-financial-results 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/256/eyenovia-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2018-financial-results 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/257/eyenovia-to-participate-in-two-upcoming-investor-conferences 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/258/eyenovia-announces-confirmatory-results-from-second-microstat-phase-iii-registration-study-for-mydriasis 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/259/eyenovia-confirms-expanded-microprost-phase-iii-indication-to-enroll-broad-patient-population-for-iop-lowering 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/260/eyenovia-announces-fda-acceptance-of-ind-application-for-micropine-to-reduce-the-progression-of-myopia 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/261/eyenovia-announces-positive-results-in-the-microstat-mist-1phase-iii-registration-study-for-mydriasis 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/262/eyenovia-prices-public-offering-of-common-stock 2025-11-25T10:41:47-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/263/eyenovia-completes-patient-enrollment-in-microstat-mist-1-study-and-enrolls-first-patient-in-mist-2-study 2025-11-25T10:41:48-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/264/eyenovia-announces-publication-of-its-pg21-phase-ii-trial-results-demonstrating-robust-iop-lowering-effect-and-patient-usability 2025-11-25T10:41:48-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/265/eyenovia-initiates-phase-iii-microstat-program-for-pharmacologic-mydriasis-enrolls-first-patient-in-mist-1-study 2025-11-25T10:41:48-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/266/eyenovia-announces-fda-acceptance-of-microstat-ind-application-for-mydriasis 2025-11-25T10:41:48-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/267/eyenovia-reports-third-quarter-2018-financial-results 2025-11-25T10:41:48-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/268/eyenovia-announces-conference-call-and-webcast-for-third-quarter-2018-financial-results 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/269/eyenovia-to-present-at-the-ophthalmology-innovation-summit-at-the-american-academy-of-ophthalmology-2018 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/270/eyenovia-to-participate-in-panel-presentation-at-osn-new-york-2018 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/271/eyenovia-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/272/eyenovia-to-present-at-the-20th-annual-h-c-wainwright-global-investment-conference 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/273/eyenovia-reports-second-quarter-2018-financial-results 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/274/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-robust-intraocular-pressure-lowering-and-patient-usability 2025-11-25T10:41:49-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/275/eyenovia-announces-conference-call-and-webcast-for-second-quarter-2018-financial-results 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/276/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing-ahead-of-initiation-of-multiple-phase-iii-programs 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/277/eyenovia-to-present-at-the-jmp-securities-2018-life-sciences-conference 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/278/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/279/eyenovia-reports-first-quarter-2018-financial-results-and-completion-of-eyn-pg21-study 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/280/eyenovia-announces-conference-call-and-webcast-for-first-quarter-2018-financial-results 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/281/eyenovia-announces-fourth-quarter-and-full-year-2017-financial-results 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/282/eyenovia-appoints-three-industry-veterans-to-board-of-directors 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/283/eyenovia-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2017-financial-results 2025-11-25T10:41:50-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/284/eyenovia-to-present-at-the-30th-annual-roth-conference 2025-11-25T10:41:51-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/285/eyenovia-advances-micropine-for-myopia-into-phase-iii-clinical-development-and-appoints-stanford-professor-dr-douglas-fredrick-to-its-scientific-advisory-board-and-myopia-program-steering-committee 2025-11-25T10:41:51-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/286/eyenovia-announces-closing-of-27-3-million-initial-public-offering 2025-11-25T10:41:51-05:00 https://ir.hyperiondefi.com/news-events/press-releases/detail/287/eyenovia-announces-pricing-of-initial-public-offering 2025-11-25T10:41:51-05:00 https://ir.hyperiondefi.com/news-events/ir-calendar/detail/20260326-fourth-quarter-2025-earnings-call 2026-03-17T09:57:56-04:00 https://ir.hyperiondefi.com/news-events/ir-calendar/detail/20251113-third-quarter-2025-earnings-call 2025-12-08T17:00:11-05:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-038601/tm2610800-1_4seq2.html 2026-04-01T17:01:02-04:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-038248/primary_doc.html 2026-04-01T08:33:53-04:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-036286/hypd-20251231x10k.htm 2026-03-30T06:06:57-04:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-034858/tm269775d1_8k.htm 2026-03-26T07:02:08-04:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-022459/primary_doc.html 2026-03-03T06:06:23-05:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-013122/primary_doc.html 2026-02-11T10:17:49-05:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-010545/primary_doc.html 2026-02-05T06:05:47-05:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-002860/tm262924-2_4seq1.html 2026-01-12T16:03:42-05:00 https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-26-002857/tm262924-1_3seq1.html 2026-01-12T16:01:47-05:00 https://ir.hyperiondefi.com/news-events/presentations/detail/33215/hypd-q3-2025-earnings-supplement 2025-11-11T00:00:00-05:00 https://ir.hyperiondefi.com/news-events/presentations/detail/33247/hypd-q4-2025-and-fy-2025-earnings-supplement 2026-03-26T00:00:00-04:00 https://ir.hyperiondefi.com/disclaimer https://ir.hyperiondefi.com/sitemap https://ir.hyperiondefi.com/accessibility-statement